

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



利君國際醫藥(控股)有限公司

Lijun International Pharmaceutical (Holding) Co., Ltd.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

ANNOUNCEMENT AND RESUMPTION OF TRADING

This statement is made at the request of The Stock Exchange of Hong Kong Limited. The board of directors (the “Board”) have noted the increases in share price and trading volume of Lijun International Pharmaceutical (Holding) Co., Ltd. (the “Company”) during trading on 6 November 2009 and wish to state that save for disclosed herein, the Board are not aware of any reasons for such increases.

Enerxin Capsule, which is developed and researched by Shijiazhuang No.4 Pharmaceutical Co., Ltd. (“Shijiazhuang No.4 Pharma”), a wholly-owned subsidiary of the Company, has been recognized by the State Key Laboratory of Virology for effective restraint of the growth of Influenza A(H1N1) on 31 October 2009.

Enerxin Capsule (generic name: Arbidol Hydrochloride Capsule) is a new antiviral drug developed and researched by Shijiazhuang No.4 Pharma and is a State Class II Prescription New Drug, and was granted National New Drug Certificate and Production Permit in October 2004. After a total of more than 200 clinical trials to this medicine conducted by Beijing Union Medical College Hospital, China-Japan Friendship Hospital and General Hospital of the Air Force of the Chinese People’s Liberation Army, the results show that Enerxin Capsule can shorten the duration of the disease and relieve the severity of symptoms when using in the early stage after the outbreak of flu, and it is suitable for the promotion in clinical use due to its excellent safety and tolerance.

In addition, the Institute of Virology, Wuhan University (State Key Laboratory of Virology) conducted a series of Pharmacodynamics trials during the period from July 2009 to September 2009, the results showed that Enerxin Capsule had an obvious function on the restraint of the growth of Influenza A(H1N1) in cells. The function of this medicine on the block of the invasion of cells by influenza A virus is the same as that of Tamiflu. The function of Enerxin Capsule on the block of the invasion of cells by Influenza A(H1N1) is stronger than its function on the restraint of virus biosynthesis.

Enerxin Capsule is a key product that the Group has been focusing on promotion. It has been disclosed in 2009 Interim Report and 2008 Annual Report. The Group believes that Enerxin Capsule has a promising market prospect.

Save for the above, we confirm that there are no negotiations or agreements relating to intended acquisitions or realizations which are discloseable under Rule 13.23 of The Rules Governing the Listing of Securities on the Stock Exchange (the "Listing Rules"), neither is the Board aware of any matter discloseable under the general obligation imposed by Rule 13.09 of the Listing Rules, which is or may be of a price-sensitive nature.

Made by the order of the Board, the directors of which individually and jointly accept responsibility for the accuracy of this statement.

Trading in the Shares on the Stock Exchange was suspended with effect from 11:26 a.m. on Friday, 6 November 2009 at the request of the Company pending the publication of this announcement. An application has been made to the Stock Exchange for the resumption of trading in the Shares on the Stock Exchange with effect from 9:30 a.m. on Monday, 9 November 2009.

By order of the Board
Sze Wing Kin, Pierre
Company Secretary

Hong Kong, 6 November 2009

As at the date of this announcement, the Board comprises Mr. Wu Qin, Mr. Qu Jiguang, Mr. Huang Chao, Mr. Xie Yunfeng, Ms. Sun Xinglai, Mr. Wang Xianjun, Mr. Duan Wei, Ms. Zhang Guifu, Mr. Bao Leyuan and Ms. Gao Shuping as executive Directors, Mr. Liu Zhiyong as non-executive Director, and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.